Trial · NCT03449251
Registered outcomes58
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
41 to 58 of 58
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (C-peptide) | Visit 2 to visit 5, over a period of up to 14 weeks | C-peptide, in pmol/L |
| Secondary | Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Glucagon) | Visit 2 to visit 5, over a period of up to 14 weeks | Glucagon, in pg/ml |
| Secondary | Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Insulin) | Visit 2 to visit 5, over a period of up to 14 weeks | Insulin, in pmol/L |
| Secondary | Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (TNF alpha) | Visit 2 to visit 5, over a period of up to 14 weeks | TNF alpha, in pg/ml |
| Secondary | Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Ratio) | Visit 2 to visit 3, over a period of up to 10 weeks | Ratio,expressed as a number (no units as this is a ratio) |
| Secondary | Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Absolute Flow) | Visit 2 to visit 3, over a period of up to 10 weeks | Absolute flow in the infused arm, in mg/dL/min |
| Secondary | Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Percentage Change) | Visit 2 to visit 3, over a period of up to 10 weeks | Percentage change in the infused arm, In % |
| Secondary | Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Echocardiography) | Visit 2 to visit 4, over a period of up to 8 weeks | Cardiac output measured by Echocardiography, in L/min |
| Secondary | Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Bioimpedance) | Visit 2 to visit 4, over a period of up to 8 weeks | Cardiac output measured by bioimpedance, in L/min |
| Secondary | Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Innocor) | Visit 2 to visit 4, over a period of up to 8 weeks | Cardiac output measured by Innocor, in L/min |
| Secondary | Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Echocardiography) | Visit 2 to visit 4, over a period of up to 8 weeks | Cardiac output measured by Echocardiography, in L/min |
| Secondary | Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Bioimpedance) | Visit 2 to visit 4, over a period of up to 8 weeks | Cardiac output measured by bioimpedance, in L/min |
| Secondary | Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Innocor) | Visit 2 to visit 4, over a period of up to 8 weeks | Cardiac output measured by Innocor, in L/min |
| Secondary | Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Glucose) | Visit 2 to visit 4, over a period of up to 8 weeks | Glucose, in mmol/L |
| Secondary | Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (C-peptide) | Visit 2 to visit 4, over a period of up to 8 weeks | C-peptide, in pmol/L |
| Secondary | Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Glucagon) | Visit 2 to visit 4, over a period of up to 8 weeks | Glucagon, in pg/ml |
| Secondary | Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Insulin) | Visit 2 to visit 4, over a period of up to 8 weeks | Insulin, in pmol/L |
| Secondary | Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (TNF alpha) | Visit 2 to visit 4, over a period of up to 8 weeks | TNF alpha, glucose homeostasis |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03449251/registered?page=3